Eduardo Aguera-Morales

Prof. Dr. Eduardo Aguera-Morales

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
ETEdmond Teng
Edmond Teng
PMPaul T. Manser
Paul T. Manser
KPKaren Pickthorn
Karen Pickthorn
FBFlavia Brunstein
Flavia Brunstein
MBMira Blendstrup
Mira Blendstrup
DWDavid Weisman
David Weisman
Numerous neurodegenerative diseases are characterized by intracellular aggregation of hyperphosphorylated tau protein,1 including Alzheimer disease (AD), in which pathological tau deposition primarily manifests as neurofibrillary tangles.2 Tau is an attractive therapeutic target in AD, as both neuropathological3,4 and tau positron emission tomography (PET)5,6 studies demonstrate significant correlations between cerebral tau pathology and clinical disease severity.

1 September 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
DCDiego Cadavid
Diego Cadavid
MMMichelle Mellion
Michelle Mellion
RHRaymond Hupperts
Raymond Hupperts
KEKeith R Edwards
Keith R Edwards
PCPeter A Calabresi
Peter A Calabresi
TZTomasz Zielinski
Tomasz Zielinski

1 April 2012 in Clinical Biochemistry
Verified
Journal Article
Closed access
ITInmaculada Tasset
Inmaculada Tasset
EAEduardo Aguera-Morales
Eduardo Aguera-Morales
FSFernando Sánchez-López
Fernando Sánchez-López
MFMontserrat Feijóo
Montserrat Feijóo
AGAna I. Giraldo
Ana I. Giraldo
ITIsaac Túnez
Isaac Túnez

5 June 2022 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
AMAna Muñoz-Jurado
Ana Muñoz-Jurado
BEBegoña M. Escribano
Begoña M. Escribano
JCJavier Caballero-Villarraso
Javier Caballero-Villarraso
AGAlberto Galván
Alberto Galván
EAEduardo Aguera-Morales
Eduardo Aguera-Morales
ITIsaac Túnez
Isaac Túnez

1 September 2012 in Neurological Research
Verified
Journal Article
Closed access
FSFernando Sánchez-López
Fernando Sánchez-López
ITInmaculada Tasset
Inmaculada Tasset
EAEduardo Aguera-Morales
Eduardo Aguera-Morales
MFMontserrat Feijóo
Montserrat Feijóo
RFRicardo Fernández-Bolaños
Ricardo Fernández-Bolaños
ITIsaac Túnez
Isaac Túnez
Huntington's disease (HD) is a neurodegenerative disorder for which there is no effective treatment. Oxidative stress and inflammation are known to be involved in HD, but the precise relationship between the two remains unclear. The aim of this study was to analyze oxidative stress and inflammation biomarkers in blood of patients with HD with a view to identifying potential links between them. Blood samples were collected from 13 patients with HD and from 10 age- and sex-matched controls, and the following were measured: C-reactive proteins, myeloperoxidase (MPO)/white blood cell (WBC) ratio, interleukin-6 (IL-6), thioredoxin reductase-1 (TrRd-1), thioredoxin-1 (Trx-1), total nitrites (NOx), nitric oxide synthase (NOS) and nitrotyrosine. Results showed that HD is associated to a reduction of TrRd-1 and Trx-1 levels in plasma and erythrocytes, and with an increase in the MPO/WBC ratio. A positive correlation was observed between global oxidative stress (GOS) and MPO/WBC. No changes were found in NOS and Nox levels with respect to controls. Oxidative damage may be linked to the inflammatory response in HD, via a peripheral immune response.

1 May 2012 in Neuroscience
Verified
Journal Article
Closed access
ITI. Tasset
I. Tasset
FMFrancisco Javier Medina-Fernández
Francisco Javier Medina-Fernández
IJI. Jimena
I. Jimena
EAEduardo Aguera-Morales
Eduardo Aguera-Morales
FGF. Gascón
F. Gascón
ITI. Túnez
I. Túnez